ERBB2 and gastric cancer: Additionally, HER2-amplified GC is the most probable candidate for responding to trastuzumab treatment, as various studies have demonstrated that an antitumor effect occurs when trastuzumab is added to HER2-amplified GC cells or the corresponding xenograft models (19,28,29).